United Therapeutics (UTHR) Tops Q2 EPS by $1.07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
United Therapeutics Corp. (UTHR) PT Raised to $235 at Cowen
August 4, 2021 12:22 PM EDTCowen analyst Joseph Thome raised the price target on United Therapeutics Corp. (NASDAQ: UTHR) to $235.00 (from $230.00) while maintaining an Outperform rating following results.
The analyst commented, "Q2 financials came in above consensus expectations on the top and bottom line, supported by strong performance from... More
